Literature DB >> 22294457

Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletions.

Lan Kluwe1, Rosa Nguyen, Julia Vogt, Kathrin Bengesser, Tanja Mussotter, Reinhard E Friedrich, Kimberly Jett, Hildegard Kehrer-Sawatzki, Victor-Felix Mautner.   

Abstract

Neurofibromatosis Type 1 (NF1) is a frequent tumor suppressor gene disorder characterized by multiple benign tumors and high risk of malignancy. Internal tumor burden is a major disease-associated manifestation and can be most adequately assessed by magnetic resonance imaging of the whole body. Approximately 5% of NF1 patients have constitutional large NF1-deletions that are generally associated with more severe clinical manifestations. Here, we investigated whether these deletion patients also have more and/or larger internal tumors by assessing internal tumors and their total volume (exclusive of cutaneous and subcutaneous) in 38 NF1 deletion patients (including eight mosaic cases) and 114 age- and gender-matched NF1 patients without deletions. The incidence of internal tumors was significantly lower in mosaic deletion patients (1/8 = 13%) but did not differ between the 30 nonmosaic deletion patients and the 90 age- and gender-matched NF1 patients without large deletions used as controls. Neither the number nor the total volume of tumors per patient differed significantly between the latter two groups. However, extremely high tumor burden (>3,000 ml) was significantly more frequent among nonmosaic NF1 deletion patients than among NF1 patients without large deletions (13% vs. 1%, P = 0.014). Thus, as a group, patients with NF1 deletions do not exhibit a significantly higher internal tumor burden than NF1 patients without such deletions. However, deletion patients can frequently have extremely large internal tumors and thus demand special attention.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22294457     DOI: 10.1002/gcc.21931

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

1.  Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging.

Authors:  Lennart Well; Johannes Salamon; Michael G Kaul; Said Farschtschi; Jochen Herrmann; Karin I Geier; Christian Hagel; Maximilian Bockhorn; Peter Bannas; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

Review 2.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

Review 3.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

4.  Clinicopathologic implications of NF1 gene alterations in diffuse gliomas.

Authors:  M Adelita Vizcaíno; Smit Shah; Charles G Eberhart; Fausto J Rodriguez
Journal:  Hum Pathol       Date:  2015-05-30       Impact factor: 3.466

Review 5.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

6.  Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions.

Authors:  Hildegard Kehrer-Sawatzki; Julia Vogt; Tanja Mußotter; Lan Kluwe; David N Cooper; Victor-Felix Mautner
Journal:  Neurogenetics       Date:  2012-05-13       Impact factor: 2.660

7.  Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.

Authors:  Johannes Salamon; László Papp; Zoltán Tóth; Azien Laqmani; Ivayla Apostolova; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

8.  Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.

Authors:  Shivani Ahlawat; Laura M Fayad; Muhammad Shayan Khan; Miriam A Bredella; Gordon J Harris; D Gareth Evans; Said Farschtschi; Michael A Jacobs; Avneesh Chhabra; Johannes M Salamon; Ralph Wenzel; Victor F Mautner; Eva Dombi; Wenli Cai; Scott R Plotkin; Jaishri O Blakeley
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

9.  Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.

Authors:  Tanja Mußotter; Lan Kluwe; Josef Högel; Rosa Nguyen; David N Cooper; Victor-Felix Mautner; Hildegard Kehrer-Sawatzki
Journal:  BMC Med Genet       Date:  2012-10-26       Impact factor: 2.103

10.  Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis.

Authors:  Laura M Fayad; Jaishri Blakeley; Scott Plotkin; Brigitte Widemann; Michael A Jacobs
Journal:  ISRN Radiol       Date:  2013-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.